Regulators approve the first cancer-killing virus

Regulators in the United States and Europe have approved Amgen’s talimogene laherparepvec, a genetically modified live oncolytic herpesvirus therapy that replicates inside cancer cells and causes them to rupture and die. More information here.

Print Friendly, PDF & Email